10057458Stella+ - Integrating a HRT prescribing decision tool in primary care workflowsClosedCollaborative R&DInnovate UKVira is motivated to make lives happier, healthier and more productive for the 1bn women worldwide (13m UK) coping with menopause. 80%+ report symptoms interfere with daily life and 50% say it has made work difficult or untenable, with 900k UK women quitting jobs annually. Symptoms include physical (hot flushes, weight gain, loss of libido) and psychological (mood swings, difficulty concentrating, depression, anxiety). Menopause can have severe long-term health implications: issues affecting women in later life, including cardiovascular disease, diabetes, osteoporosis and dementia, can be triggered at menopause. Improving treatment for menopause is urgently needed if we are to tackle these early on. The current care model is broken, with <10% of UK women saying they are happy with the care they receive. Fixing the model is a key priority of the All-Party Parliamentary Group on Menopause, which sets out need for urgent help for women: boosting support in the workplace, training on symptoms for health workers, improving access to treatment, and checks for all women at 45\. To address this, Vira has devised its Stella platform: Our first product, _Stella_, is a personalised menopause treatment and coaching app for women, and is already transforming symptom management. It enables women to access support --individually or via B2B subscriptions made by their workplace -- including exercise and diets plans, information, online yoga classes, access to cognitive behaviour therapy, etc. This project addresses the specific problems of training health practitioners and improving access to treatment by delivering Stella+. Stella+ is a clinical assessment tool for menopause, designed to support GPs and allied health professionals in making better decisions about prescriptions of hormone replacement therapy (HRT), and to optimise treatment review processes, with better identification of treatment ineffectiveness, side and adverse effects. Stella+ will build upon our Class IIa algorithms for prescribing HRT.